Form 4: Vaxcyte CFO Andrew Guggenhime Executes Stock Option and Sells Shares Under 10b5-1 Plan

Vaxcyte's CFO, Andrew Guggenhime, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan on July 18, 2024.

Summary

• On July 18, 2024, Andrew Guggenhime, the President and CFO of Vaxcyte, Inc., exercised stock options to acquire 8,000 shares of common stock at a price of $5.35 per share.
• Guggenhime then sold 8,000 shares of common stock in multiple transactions at weighted average prices ranging from $80.115 to $83.137.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 30, 2023.
• Following these transactions, Guggenhime directly owns 96,720 shares of Vaxcyte common stock and holds options for 336,827 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reports routine transactions under a pre-arranged plan. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• While the transactions are under a 10b5-1 plan, large sales by executives can sometimes be perceived negatively by the market.

Future Outlook

There is no specific future outlook provided in this document, as it is a report of past transactions.

Industry Context

Insider transactions are common in publicly traded companies, and the use of 10b5-1 plans is a standard practice to allow insiders to sell shares while avoiding accusations of trading on non-public information. Investors often monitor these filings for insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Executive compensation packages often include stock options, aligning management's interests with those of shareholders.
• Rule 10b5-1 trading plans are a common tool used by executives at companies like Moderna, BioNTech, and Novavax to manage their stock holdings and avoid insider trading concerns.
• The size and frequency of insider transactions can vary widely depending on the company's stage of development, executive compensation policies, and individual financial planning needs.

Stakeholder Impact

• Shareholders may monitor these transactions for insights into management's confidence in the company.
• The transactions themselves are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates